Global Epilepsy Drug Market

Epilepsy Drug Comprehensive Study by Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Application (Hospital, Research), Drug activity spectrum (Narrow spectrum drugs, Broad spectrum drugs) Players and Region - Global Market Outlook to 2022

Epilepsy Drug Market by XX Submarkets | Forecast Years 2021-2026 | CAGR: 3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Epilepsy is known as a brain disorder which is characterised by the spontaneously occurring and recurrent seizures. Seizures result from the abnormal electrical discharges in the brain. Epilepsy can also be considered as a spectrum disorder due to its different causes, different types of seizure and different disease severities. Many different epilepsy syndromes have been characterised, with some of these syndromes which are appearing to be hereditary. The market of the epilepsy drug is rising due to the rising advancement in technology

The research analyst at AMA estimates Epilepsy Drug market to grow at a compounded annual growth rate of 3.0%

Market Drivers
  • Advances in the understanding of epilepsy pathology
  • Emerging market growth, rising old age population, increasing incidences of accidents globally

Market Trend
  • Increasing costs of epilepsy management
  • Modification of Existing Epilepsy Drugs

Restraints
  • High directs costs
  • Threatening expiration of drug patents
  • The drugs can cause dizziness, nausea, headache, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor

Opportunities
The high annual cost of therapy for pipeline drugs means they will generate high sales and drive growth

Players Covered in the Study are:
Pfizer (United States), Eisai (Japan), Novartis (Switzerland), Sanofi (France), Union Chimique Belge (Belgium), Abbott (United States), GlaxoSmithKline (United Kingdom), Sunovion Pharmaceuticals (United States) and Teva Pharmaceutical (Israel)

The Global Epilepsy Drug market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Industry Insights:
Pfizer Acquired Hospira, Inc., Ferrer Pharma Acquired Alexza Pharmaceuticals, Zogenix Acquired Brabant Pharma and Sawai Pharmaceutical Acquired Upsher-Smith Laboratories


Report Objectives / Segmentation Covered

By Type
  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs
By Application
  • Hospital
  • Research
By Drug activity spectrum
  • Narrow spectrum drugs
  • Broad spectrum drugs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Advances in the understanding of epilepsy pathology
      • 3.2.2. Emerging market growth, rising old age population, increasing incidences of accidents globally
    • 3.3. Market Challenges
      • 3.3.1. The low safety profile of AEDs
      • 3.3.2. High power drugs can possess a threat
    • 3.4. Market Trends
      • 3.4.1. Increasing costs of epilepsy management
      • 3.4.2. Modification of Existing Epilepsy Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Epilepsy Drug, by Type, Application, Drug activity spectrum and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Epilepsy Drug (Value)
      • 5.2.1. Global Epilepsy Drug by: Type (Value)
        • 5.2.1.1. First Generation Drugs
        • 5.2.1.2. Second Generation Drugs
        • 5.2.1.3. Third Generation Drugs
      • 5.2.2. Global Epilepsy Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Research
      • 5.2.3. Global Epilepsy Drug by: Drug activity spectrum (Value)
        • 5.2.3.1. Narrow spectrum drugs
        • 5.2.3.2. Broad spectrum drugs
      • 5.2.4. Global Epilepsy Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Epilepsy Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eisai (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Union Chimique Belge (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sunovion Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Epilepsy Drug Sale, by Type, Application, Drug activity spectrum and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Epilepsy Drug (Value)
      • 7.2.1. Global Epilepsy Drug by: Type (Value)
        • 7.2.1.1. First Generation Drugs
        • 7.2.1.2. Second Generation Drugs
        • 7.2.1.3. Third Generation Drugs
      • 7.2.2. Global Epilepsy Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Research
      • 7.2.3. Global Epilepsy Drug by: Drug activity spectrum (Value)
        • 7.2.3.1. Narrow spectrum drugs
        • 7.2.3.2. Broad spectrum drugs
      • 7.2.4. Global Epilepsy Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Epilepsy Drug: by Type(USD Billion)
  • Table 2. Epilepsy Drug First Generation Drugs , by Region USD Billion (2013-2018)
  • Table 3. Epilepsy Drug Second Generation Drugs , by Region USD Billion (2013-2018)
  • Table 4. Epilepsy Drug Third Generation Drugs , by Region USD Billion (2013-2018)
  • Table 5. Epilepsy Drug: by Application(USD Billion)
  • Table 6. Epilepsy Drug Hospital , by Region USD Billion (2013-2018)
  • Table 7. Epilepsy Drug Research , by Region USD Billion (2013-2018)
  • Table 8. Epilepsy Drug: by Drug activity spectrum(USD Billion)
  • Table 9. Epilepsy Drug Narrow spectrum drugs , by Region USD Billion (2013-2018)
  • Table 10. Epilepsy Drug Broad spectrum drugs , by Region USD Billion (2013-2018)
  • Table 11. South America Epilepsy Drug, by Country USD Billion (2013-2018)
  • Table 12. South America Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 13. South America Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 14. South America Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 15. Brazil Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 16. Brazil Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 17. Brazil Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 18. Argentina Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 19. Argentina Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 20. Argentina Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 21. Rest of South America Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 22. Rest of South America Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 23. Rest of South America Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 24. Asia Pacific Epilepsy Drug, by Country USD Billion (2013-2018)
  • Table 25. Asia Pacific Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 26. Asia Pacific Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 27. Asia Pacific Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 28. China Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 29. China Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 30. China Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 31. Japan Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 32. Japan Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 33. Japan Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 34. India Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 35. India Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 36. India Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 37. South Korea Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 38. South Korea Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 39. South Korea Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 40. Taiwan Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 41. Taiwan Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 42. Taiwan Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 43. Australia Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 44. Australia Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 45. Australia Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 46. Rest of Asia-Pacific Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 47. Rest of Asia-Pacific Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 48. Rest of Asia-Pacific Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 49. Europe Epilepsy Drug, by Country USD Billion (2013-2018)
  • Table 50. Europe Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 51. Europe Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 52. Europe Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 53. Germany Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 54. Germany Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 55. Germany Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 56. France Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 57. France Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 58. France Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 59. Italy Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 60. Italy Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 61. Italy Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 62. United Kingdom Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 63. United Kingdom Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 64. United Kingdom Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 65. Netherlands Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 66. Netherlands Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 67. Netherlands Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 68. Rest of Europe Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 69. Rest of Europe Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 70. Rest of Europe Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 71. MEA Epilepsy Drug, by Country USD Billion (2013-2018)
  • Table 72. MEA Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 73. MEA Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 74. MEA Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 75. Middle East Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 76. Middle East Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 77. Middle East Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 78. Africa Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 79. Africa Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 80. Africa Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 81. North America Epilepsy Drug, by Country USD Billion (2013-2018)
  • Table 82. North America Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 83. North America Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 84. North America Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 85. United States Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 86. United States Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 87. United States Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 88. Canada Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 89. Canada Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 90. Canada Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 91. Mexico Epilepsy Drug, by Type USD Billion (2013-2018)
  • Table 92. Mexico Epilepsy Drug, by Application USD Billion (2013-2018)
  • Table 93. Mexico Epilepsy Drug, by Drug activity spectrum USD Billion (2013-2018)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Epilepsy Drug: by Type(USD Billion)
  • Table 104. Epilepsy Drug First Generation Drugs , by Region USD Billion (2019-2024)
  • Table 105. Epilepsy Drug Second Generation Drugs , by Region USD Billion (2019-2024)
  • Table 106. Epilepsy Drug Third Generation Drugs , by Region USD Billion (2019-2024)
  • Table 107. Epilepsy Drug: by Application(USD Billion)
  • Table 108. Epilepsy Drug Hospital , by Region USD Billion (2019-2024)
  • Table 109. Epilepsy Drug Research , by Region USD Billion (2019-2024)
  • Table 110. Epilepsy Drug: by Drug activity spectrum(USD Billion)
  • Table 111. Epilepsy Drug Narrow spectrum drugs , by Region USD Billion (2019-2024)
  • Table 112. Epilepsy Drug Broad spectrum drugs , by Region USD Billion (2019-2024)
  • Table 113. South America Epilepsy Drug, by Country USD Billion (2019-2024)
  • Table 114. South America Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 115. South America Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 116. South America Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 117. Brazil Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 118. Brazil Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 119. Brazil Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 120. Argentina Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 121. Argentina Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 122. Argentina Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 123. Rest of South America Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 124. Rest of South America Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 125. Rest of South America Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 126. Asia Pacific Epilepsy Drug, by Country USD Billion (2019-2024)
  • Table 127. Asia Pacific Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 128. Asia Pacific Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 129. Asia Pacific Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 130. China Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 131. China Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 132. China Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 133. Japan Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 134. Japan Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 135. Japan Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 136. India Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 137. India Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 138. India Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 139. South Korea Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 140. South Korea Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 141. South Korea Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 142. Taiwan Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 143. Taiwan Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 144. Taiwan Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 145. Australia Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 146. Australia Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 147. Australia Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 148. Rest of Asia-Pacific Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 149. Rest of Asia-Pacific Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 150. Rest of Asia-Pacific Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 151. Europe Epilepsy Drug, by Country USD Billion (2019-2024)
  • Table 152. Europe Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 153. Europe Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 154. Europe Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 155. Germany Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 156. Germany Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 157. Germany Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 158. France Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 159. France Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 160. France Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 161. Italy Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 162. Italy Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 163. Italy Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 164. United Kingdom Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 165. United Kingdom Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 166. United Kingdom Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 167. Netherlands Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 168. Netherlands Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 169. Netherlands Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 170. Rest of Europe Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 171. Rest of Europe Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 172. Rest of Europe Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 173. MEA Epilepsy Drug, by Country USD Billion (2019-2024)
  • Table 174. MEA Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 175. MEA Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 176. MEA Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 177. Middle East Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 178. Middle East Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 179. Middle East Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 180. Africa Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 181. Africa Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 182. Africa Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 183. North America Epilepsy Drug, by Country USD Billion (2019-2024)
  • Table 184. North America Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 185. North America Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 186. North America Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 187. United States Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 188. United States Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 189. United States Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 190. Canada Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 191. Canada Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 192. Canada Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 193. Mexico Epilepsy Drug, by Type USD Billion (2019-2024)
  • Table 194. Mexico Epilepsy Drug, by Application USD Billion (2019-2024)
  • Table 195. Mexico Epilepsy Drug, by Drug activity spectrum USD Billion (2019-2024)
  • Table 196. Research Programs/Design for This Report
  • Table 197. Key Data Information from Secondary Sources
  • Table 198. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Epilepsy Drug: by Type USD Billion (2013-2018)
  • Figure 5. Global Epilepsy Drug: by Application USD Billion (2013-2018)
  • Figure 6. Global Epilepsy Drug: by Drug activity spectrum USD Billion (2013-2018)
  • Figure 7. South America Epilepsy Drug Share (%), by Country
  • Figure 8. Asia Pacific Epilepsy Drug Share (%), by Country
  • Figure 9. Europe Epilepsy Drug Share (%), by Country
  • Figure 10. MEA Epilepsy Drug Share (%), by Country
  • Figure 11. North America Epilepsy Drug Share (%), by Country
  • Figure 12. Global Epilepsy Drug share by Players 2018 (%)
  • Figure 13. Global Epilepsy Drug share by Players (Top 3) 2018(%)
  • Figure 14. Global Epilepsy Drug share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer (United States) Revenue: by Geography 2018
  • Figure 18. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 19. Eisai (Japan) Revenue: by Geography 2018
  • Figure 20. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 22. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi (France) Revenue: by Geography 2018
  • Figure 24. Union Chimique Belge (Belgium) Revenue, Net Income and Gross profit
  • Figure 25. Union Chimique Belge (Belgium) Revenue: by Geography 2018
  • Figure 26. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 27. Abbott (United States) Revenue: by Geography 2018
  • Figure 28. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 30. Sunovion Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Sunovion Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 32. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 33. Teva Pharmaceutical (Israel) Revenue: by Geography 2018
  • Figure 34. Global Epilepsy Drug: by Type USD Billion (2013-2018)
  • Figure 35. Global Epilepsy Drug: by Application USD Billion (2013-2018)
  • Figure 36. Global Epilepsy Drug: by Drug activity spectrum USD Billion (2013-2018)
  • Figure 37. South America Epilepsy Drug Share (%), by Country
  • Figure 38. Asia Pacific Epilepsy Drug Share (%), by Country
  • Figure 39. Europe Epilepsy Drug Share (%), by Country
  • Figure 40. MEA Epilepsy Drug Share (%), by Country
  • Figure 41. North America Epilepsy Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Eisai (Japan)
  • Novartis (Switzerland)
  • Sanofi (France)
  • Union Chimique Belge (Belgium)
  • Abbott (United States)
  • GlaxoSmithKline (United Kingdom)
  • Sunovion Pharmaceuticals (United States)
  • Teva Pharmaceutical (Israel)
Select User Access Type

Key Highlights of Report


Jan 2019 230 Pages 56 Tables Base Year: 2020 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Epilepsy Drug Market Quantitative research analysis
Global Epilepsy Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Epilepsy Drug Market Report?

Have a Query? Click Here

Other Related Reports

Medical Marijuana Comprehensive Study by Type (Buds, Oil, Tinctures), Application (Chronic Pain, Mental Disorders, Arthritis, Migraine, Cancer, Other), Marijuana Type (Medical Marijuana, Recreational...
$ 3500
Orphan Drugs Comprehensive Study by Drug Type (Biologics, Non-Biologics), Sale (Generics, Prescribed), Drugs (Revlimid, Rituxan, Opdivo, Others), Disease Type (Oncology, Gastrointestinal, Pulmonary, ...
$ 3750
Diptheria Vaccine Comprehensive Study by Type (Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quaracel), Disease Type (Diphtheria, Tetanus, Pertussis), Packaging Type (0.5 ML, 1 ML, 2 ML, Others), A...
$ 3450
Bio-pharma Comprehensive Study by Type (Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, G...
$ 3750
Polio Vaccines Comprehensive Study by Type (IPV (Inactivated Poliovirus Vaccine), OPV (Oral Polio Vaccine)), Application (Hospital, Clinics, Public Services, Others) Players and Region - Global Marke...
$ 3500
Impetigo Drug Comprehensive Study by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin, Others), Route of Administration (Topical, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail ...
$ 3500